The Courage Study (NCT04575766) is a multicenter, phase 1 open-label study evaluating the safety, pharmacokinetics (PK), preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed amidst prior treatment and have been treated with at least one approved androgen receptor pathway inhibitor (NCT04575766). The gene discussed is AR; the disease is neoplasm.